Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis (NCT05201638)

🧪 Interventions in This Study

• IMU-838 tablets (DRUG)
• Placebo matching IMU-838 tablets (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (76 Sites)

Showing the first 25 of 76 sites.

• Neuro of Central Florida — Altamonte Springs, Florida
• Healthcare Innovations — Coral Springs, Florida
• Heratsi Hospital Complex 1 — Yerevan,
• Saint Gregory the Illuminator Medical Center — Yerevan,
• Erebouni Medical Center — Yerevan,
• UCC of Rep of Srpska — Banja Luka,
• Cantonal Hospital Bihac Dr. Irfan Ljubijankic — Bihać,
• University Clinical Center of Sarajevo — Sarajevo,
• University Clinical Center Sarajevo — Sarajevo,
• University Clinical Center Tuzla — Tuzla,
• Astra Clinic — Tallinn,
• University Hospital Muenster, Institute Translational Neurology dept. Neurology — Münster,
• Post-Graduation Institute of Medical Education and Research (PGIMER) — Chandigarh,
• Fortis Memorial Research Institute — Gurugramam,
• Polakulath Narayanan Renai Medicity MSSH — Kochi,
• Dr Ram Manohar Lohia Institute of Medical Sciences — Lucknow,
• All India Institute of Medical Sciences — New Delhi,
• GB Pant Institute of Postgraduate Medical Education and Research — New Delhi,
• SRI Guru Ram Das Institute of Medical Sciences and Research — Punjābi Bāgh,
• DKS PGI — Raipur,
• Hospital Nacional Dos de Mayo — Lima,
• NZOZ Novo-Med — Katowice,
• NZOZ Wielospecjalistyczna Poradnia Lekarska "Synapsis" — Katowice,
• Neuro-Medic Janusz Zbrojkiewicz — Katowice,
• NZOZ Neuromed — Lublin,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Multiple Sclerosis, Relapsing-Remitting

• Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS — Aurora, Colorado
• Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial — Birmingham, Alabama
• A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis — La Jolla, California
• A Post-Authorization, Long-term Study of Ozanimod Real-world Safety — Bethesda, Maryland
• Efficacy of Diet on Quality of Life in Multiple Sclerosis — Iowa City, Iowa

Explore by condition: All Multiple Sclerosis, Relapsing-Remitting clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.